Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 4/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | CCKBR | P32239 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24394129 | 0.88 | PTGDR (0.31) | FFAR4PTGDR2 | |
| SCHEMBL24394126 | 0.86 | — | — | |
| SCHEMBL24394132 | 0.84 | L3MBTL1 (0.33) | — | |
| SCHEMBL24394125 | 0.84 | ALDH1A1 (0.30) | FFAR4 | |
| SCHEMBL24801183 | 0.81 | — | — | |
| SCHEMBL24394133 | 0.79 | — | — | |
| SCHEMBL26929350 | 0.79 | — | — | |
| SCHEMBL24393987 | 0.79 | EPHX2 (0.36) | — | |
| SCHEMBL24394122 | 0.79 | FFAR4 (0.36) | FFAR4PTGDR2 | |
| SCHEMBL24801652 | 0.79 | GRM4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| EP-4237408-A1 | ITACONIC ACID DERIVATIVES | Sitryx Therapeutics Limited (GB) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022090723-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022090723-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | IL1R1, LRBA, HCAR1 | FABP4 2460/4885FFAR4 824/4885MCL1 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.